Monday, March 30, 2009


Eli Lilly to continue schizophrenia drug program. No real news here; given the state of the world we are living in, if it were up to me I would make it the top priority project . What's way more interesting is the rationale behind the decision. They are calling their trial studies "inconclusive" although the drug was no more effective than placebo (i.e. the generally accepted definition of a useless drug). The reason? Get this: "the unusually high response rate from patients taking placebo"!!! In a brilliant marketing move, by making this announement, the company has managed to increase the potential users of the drug when it finally gets approved.

1 comment:

Βάσκες said...

Now the really amazing stunt would be to manage to get approval for the placebo.

After all it is unusually effective.